Nomathemba Chandiwana to Female
This is a "connection" page, showing publications Nomathemba Chandiwana has written about Female.
Connection Strength
0,445
-
Weight Gain After HIV Therapy Initiation: Pathophysiology and Implications. J Clin Endocrinol Metab. 2024 Jan 18; 109(2):e478-e487.
Score: 0,087
-
The predicted risk of adverse pregnancy outcomes as a result of treatment-associated obesity in a hypothetical population receiving tenofovir alafenamide/emtricitabine/dolutegravir, tenofovir disoproxil fumarate/emtricitabine/dolutegravir or tenofovir disoproxil fumarate/emtricitabine/efavirenz. AIDS. 2021 12 15; 35(Suppl 2):S117-S125.
Score: 0,075
-
Unexpected interactions between dolutegravir and folate: randomized trial evidence from South Africa. AIDS. 2021 02 02; 35(2):205-211.
Score: 0,071
-
High loss to follow-up of children on antiretroviral treatment in a primary care HIV clinic in Johannesburg, South Africa. Medicine (Baltimore). 2018 Jul; 97(29):e10901.
Score: 0,059
-
DORA: 48-week weight and metabolic changes in Black women with HIV, in a phase IIIb switch study from dolutegravir- or efavirenz- to doravirine-based first-line antiretroviral therapy. HIV Med. 2025 Jan; 26(1):81-96.
Score: 0,023
-
Regional variation in weight change after the transition to dolutegravir in Uganda and South Africa. AIDS. 2024 07 15; 38(9):1314-1322.
Score: 0,022
-
Determinants of early change in serum creatinine after initiation of dolutegravir-based antiretroviral therapy in South Africa. Br J Clin Pharmacol. 2024 May; 90(5):1247-1257.
Score: 0,022
-
Stillbirth rate by maternal HIV serostatus and antiretroviral use in pregnancy in South Africa: An audit. S Afr Med J. 2021 09 02; 111(9):822-823.
Score: 0,018
-
Genetic Associations with Weight Gain among South Africans who Initiated Dolutegravir-Containing and Tenofovir-Containing Regimens. J Acquir Immune Defic Syndr. 2021 07 01; 87(3):1002-1009.
Score: 0,018
-
Experiences of doctoral students enrolled in a research fellowship program to support doctoral training in Africa (2014 to 2018): The Consortium for Advanced Research Training in Africa odyssey. PLoS One. 2021; 16(6):e0252863.
Score: 0,018
-
Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial. Lancet HIV. 2020 10; 7(10):e666-e676.
Score: 0,017
-
Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV. N Engl J Med. 2019 08 29; 381(9):803-815.
Score: 0,016